Published: May 10, 2021
May 10, 2021 11:00 UTC
Finerenone significantly reduced the risk of the composite primary endpoint of cardiovascular death and non-fatal cardiovascular events versus placebo when added to standard of care
1
FIGARO-DKD is the second positive Phase III study within the finerenone study program in CKD and T2D to meet its primary endpoint
1,2,3
Bayer’s Phase III cardiovascular outcomes study FIGARO-DKD, evaluating the efficacy and safety of the investigational drug finerenone versus placebo when added to standard of care in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) has met its primary endpoint. The study showed finerenone significantly reduced the composite risk of time to first occurrence of cardiovascular (CV) death or non-fatal CV events (myocardial infarction, stroke, or hospitalization for heart failure). The Phase III FIGARO-DKD study included more patients with earlier stage CKD and T2D compared to the FIDELIO-DKD stu
Akebia Reports First Quarter 2021 Financial Results and Highlights Recent Company Milestones
- Vadadustat New Drug Application (NDA) submitted to the U.S. Food and Drug Administration (FDA)
- Results of global Phase 3 programs for vadadustat published in New England Journal of Medicine
- Conference call today at 9:00 a.m. ET
News provided by
Share this article
®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, today reported financial results for the first quarter ended March 31, 2021 and highlighted recent corporate milestones. The Company will host a conference call today, Monday, May 10, 2021, at 9:00 a.m. Eastern Time.
Jacque Smith and Cassie Spodak, CNN, April 27, 2021
When she first learned about race correction, Naomi Nkinsi was one of five Black medical students in her class at the University of Washington.
Nkinsi remembers the professor talking about an equation doctors use to measure kidney function. The professor said eGFR equations adjust for several variables, including the patient’s age, sex and race. When it comes to race, doctors have only two options: Black or “Other.”
Nkinsi was dumbfounded.
“It was really shocking to me,” says Nkinsi, now a third-year medical and masters of public health student, “to come into school and see that not only is there interpersonal racism between patients and physicians … there’s actually racism built into the very algorithms that we use.”
To focus on comprehensive renal care J B Chemicals & Pharmaceuticals announced its foray into the area of Nephrology with a new dedicated division called RENOVA which will endeavour to serve patients who are under treatment for Chronic Kidney Disease.
The new division will focus exclusively on comprehensive renal care ranging from the management of hypertension in Chronic Kidney Disease to End-stage renal disease. After successfully becoming one of the leading player in Hypertension with brands like Cilacar and
Nicardia , JBCPL has now begun to also focus on patients with CKD.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
J B Chemicals forays into nephrology segment in India
J B Chemicals forays into nephrology segment in India
06 May 2021 | News Company to launch seven products in the division that will focus on the management of hypertension in Chronic Kidney Disease to End-stage renal disease
Image credit- shutterstock.com
J.B. Chemicals & Pharmaceuticals, based in Mumbai, has announced its foray into the area of Nephrology with a new dedicated division called “RENOVA” which will endeavour to serve patients who are under treatment for Chronic Kidney Disease.
The new division will focus exclusively on comprehensive renal care ranging from the management of hypertension in Chronic Kidney Disease to End-stage renal disease. After successfully becoming one of the leading player in Hypertension with brands like Cilacar® and Nicardia® , JBCPL has now begun to also focus on patients with CKD.